Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

906
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
906
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

410
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
410
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

817
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
817
Pulmonary Embolism I: Introduction01:29

Pulmonary Embolism I: Introduction

1.5K
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
1.5K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

615
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
615
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

689
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
689

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From case reports to a cohort: illuminating the spectrum of pulmonary hypertension in Noonan syndrome.

The European respiratory journal·2026
Same author

Eccentricity Index Is Associated With Pulmonary Arterial Hypertension in Children After Repair of Complete Atrioventricular Septal Defects.

Echocardiography (Mount Kisco, N.Y.)·2026
Same author

Macitentan in Pediatric Pulmonary Arterial Hypertension (TOMORROW): A Randomized Clinical Trial.

The Journal of pediatrics·2026
Same author

Current State of RV Multimodality Imaging in Pediatric Pulmonary Hypertension: Current Evidence, Knowledge Gaps, and Future Research Directions.

Circulation. Cardiovascular imaging·2026
Same author

Right Atrial Function is Impaired in Pediatric Pulmonary Arterial Hypertension: A Multi-center Cardiovascular Magnetic Resonance Study.

Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance·2025
Same author

Pediatric Use of Inhaled Iloprost.

Pulmonary circulation·2025

Related Experiment Video

Updated: May 4, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

13.6K

Pediatric pulmonary hypertension.

D Dunbar Ivy1, Steven H Abman2, Robyn J Barst3

  • 1Pediatric Cardiology, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado.

Journal of the American College of Cardiology
|December 21, 2013
PubMed
Summary
This summary is machine-generated.

Pediatric pulmonary hypertension (PH) is a rare, serious condition in children. Management is challenging, often relying on adult data and expert opinion due to limited pediatric-specific research.

Keywords:
APAH-CHDAVTCHDHPAHIPAHPAPmPHPHVDPPHNPVRSVRacute vasodilator testingcongenital heart diseasehereditary pulmonary arterial hypertensionidiopathic pulmonary arterial hypertensionmean pulmonary artery pressurepediatricspersistent pulmonary hypertension of the newbornpulmonary arterial hypertension associated with congenital heart diseasepulmonary hypertensionpulmonary hypertensive vascular diseasepulmonary vascular resistancesystemic vascular resistance

More Related Videos

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

6.9K
Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice
10:20

Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice

Published on: January 16, 2013

25.2K

Related Experiment Videos

Last Updated: May 4, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

13.6K
Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

6.9K
Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice
10:20

Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice

Published on: January 16, 2013

25.2K

Area of Science:

  • Pediatrics
  • Cardiology
  • Pulmonology

Background:

  • Pediatric pulmonary hypertension (PH) presents significant morbidity and mortality risks in newborns, infants, and children.
  • Commonly idiopathic or linked to congenital heart disease (CHD), PH in children rarely stems from connective tissue or thromboembolic disorders.
  • Incidence rates in the Netherlands show 0.7/4.4 and 2.2/15.6 per million children for idiopathic pulmonary arterial hypertension and PH associated with CHD, respectively.

Purpose of the Study:

  • To review the current understanding and classification of pediatric pulmonary hypertension.
  • To highlight the challenges in managing pediatric PH.
  • To emphasize the need for pediatric-specific treatment guidelines.

Main Methods:

  • Review of existing literature on pediatric pulmonary hypertension.
  • Analysis of incidence data from the Netherlands.
  • Discussion of the updated Nice classification for PH.
  • Examination of current management strategies and their limitations.

Main Results:

  • The updated Nice classification now incorporates detailed CHD categories and focuses on persistent PH of the newborn and developmental lung diseases.
  • Management strategies for pediatric PH are not well-established.
  • Treatment decisions are primarily based on adult studies and expert clinical experience.

Conclusions:

  • Pediatric PH requires specialized attention due to its unique characteristics and impact.
  • The classification of PH has evolved to better address pediatric-specific conditions.
  • Further research and development of pediatric-specific treatment guidelines are crucial for improving outcomes.